Filspari denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for filspari are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Filspari as Experimental — and Why That Characterization Is Outdated

Filspari (sparsentan) received FDA approval for IgA nephropathy (IgAN). Despite this, Aetna may issue an "experimental or investigational" denial if its internal clinical policy has not been updated to reflect the FDA approval, if the plan is applying an older policy version, or if coverage criteria have not yet been aligned with the approval date. These denials are among the most straightforward to overturn because FDA approval itself is the standard benchmark insurers use to distinguish experimental from non-experimental treatments.

An experimental denial for an FDA-approved drug is a strong candidate for both internal appeal and — if needed — external review by an independent medical expert who will assess the drug against current evidence standards.

## Your Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): File within the deadline on your denial notice. Present the FDA approval as direct rebuttal evidence.
• External review: An independent external reviewer applying generally accepted medical practice standards is likely to find that an FDA-approved drug does not meet the definition of experimental. Request external review if the internal appeal is denied. The standard window is approximately four months from the original denial.
• Expedited review: If IgAN is progressing and delay poses risk of irreversible kidney injury, request expedited review.

## Documentation to Gather

1. FDA approval documentation — the FDA approval letter or the official prescribing information for Filspari confirming its approved indication. 2. Diagnosis confirmation — biopsy-confirmed IgA nephropathy, current proteinuria levels (as recorded in chart), and kidney function trajectory. 3. Clinical guideline reference — your nephrologist can reference the relevant nephrology guideline organization generically (e.g., KDIGO) to confirm that sparsentan is recognized by the relevant medical community as a standard treatment option. 4. Prescriber medical-necessity letter — explaining why Filspari is the appropriate agent for this patient's specific clinical profile and that it is not investigational.

## Criteria-Mapping Structure

Request Aetna's clinical policy for Filspari. Then respond point-by-point:

| Aetna "Experimental" Criterion | Your Rebuttal Evidence | |---|---| | FDA approval status | [FDA approval letter / prescribing label — date of approval] | | Recognition in medical literature | [Prescriber letter + guideline organization reference] | | Diagnosis confirmed and on-label use | [Biopsy report + chart notes] | | No investigational protocol required | [Prescriber attestation] |

Present the FDA approval letter as exhibit A. A well-organized appeal that leads with FDA approval status typically resolves experimental-designation denials quickly at the internal level.